| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
08-30-2017, 02:51 AM
|
#1 | ||
|
|||
|
News Gatherer
Community Support Team
|
Xconomy FDA Refuses to Review Acorda Parkinson's Drug, Shares Tumble Xconomy The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson's disease drug that is critical to the company's future. Acorda (NASDAQ: ACOR ... FDA refuses Acorda NDA for Parkinson's drug candidate because of manufacturing issuesFiercePharma Acorda suffers embarrassing, costly delay to FDA review of Parkinson's drugSTAT Acorda Dives To 10-Week Low After FDA Refuses Parkinson's DrugInvestor's Business Daily Seeking Alpha -BioPharma Dive -TheStreet.com -Zacks Investment Research all 75 news articles » More... |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| E-Scape Unveils $63M for Alzheimer's, Parkinson's Drug Research ... - Xconomy | Parkinson's News | |||
| Acorda Leans on Parkinson's Drugs After Post-Stroke Study Fails - Xconomy | Parkinson's News | |||
FDA Refuses to Review Acorda Parkinson's Drug, Shares Tumble - Xconomy
Linear Mode
